Biotechnology company Nomic Bio has announced a partnership with Broad Clinical Labs (BCL) to build a scalable proteomics platform. The organisations will look to integrate Nomic’s Omni 1000 solution into BCL’s existing capabilities to develop new application-specific solutions. Based on nELISA technology, Nomic says Omni 1000 measures… Read More
Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance. The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More
Daniel Hornburg PhD, Vice-President Biomarkers & Precision Medicine, Bruker Daltonics, Stefan Foser, Vice President Global Pharma, Bruker Daltonics, and Torsten Müller, Business Development Manager, Proteomics, Bruker Daltonics, explore how MS-based proteomics can be used to dissect disease biology with spatial resolution. Impact of neurodegeneration for ageing societies… Read More
This article is sponsored by Standard BioTools. Neurodegenerative diseases affect more than 57 million people globally, a figure expected to double within two decades1,2. This alarming projection reflects three major clinical challenges: difficulty diagnosing disease in early, treatable stages; a lack of curative therapies; and limited treatment options2,3. Read More
Researchers have discovered that a subtle chemical change to protein p21 acts as a master regulator of cell division – a finding that could influence future cancer therapies. The study was launched at the Biotechnology Center (BIOTEC) of TUD Dresden University of Technology in Germany and later… Read More
Proteome analysis company Nautilus Biotechnology has announced a partnership with the Allen Institute focused on improving our understanding of neurodegenerative conditions. The organisations will investigate the connection between the tau protein and its occurrence in neurodegenerative conditions such as Alzheimer’s disease. Recent studies suggested that… Read More
The Global Neurodegeneration Proteomics Consortium (GNPC) has released research analyses of one of the world’s largest protein datasets in order offer new insights into the biological underpinnings of major neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The findings, published in a series of papers in Nature Medicine, reveal… Read More
Download this new brochure ‘Multiomic nanopore sequencing solutions: Revolutionising human disease research‘ to maximise the data generated from your valuable research samples. Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms… Read More
Understanding the mechanisms of disease requires complex data ranging from genomic data through to transcriptomics, epigenetics and proteomics. Legacy multiomic approaches require multiple platforms and complex processes, which are incompatible with disease research that utilises scarce tissue samples. Download the brochure to learn how multiomic nanopore sequencing can… Read More
Proteomics company Alamar Biosciences closed $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days. This new capital brings Alamar’s total funding to date to nearly $250 million. The financing round was led… Read More
Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. Professor Blackburn began by sharing an overview… Read More
This article is sponsored by Evotec. To enable Evotec’s precision medicine approach, we have been building technology platforms that allow PanOmics or multi-omics data generation at an industrialised scale. The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using… Read More
The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire… Read More
Professor Henrik Daub, Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases. Advancements in proteomics using mass spectrometry are helping researchers to identify novel, previously undruggable targets and… Read More
X-Chem and the Structural Genomics Consortium (SGC) have entered a collaboration aimed at creating new chemical tools to study human proteins. The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome – ultimately allowing drug discovery… Read More
Eurofins Genomics has adopted Olink technology to advance proteomics research and accelerate its precision medicine programmes. The collaboration is designed to bolster the company’s offerings in the fields of research, population health, and regulated clinical trials. Olink Explore HT is the company’s latest solution… Read More
